


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) ~~Use of compounds of the following formula (I)~~ A method for the treatment of treatment of postlesional diseases of ischemic, traumatic or toxic origin, comprising administering an effective amount of a compound of formula (I):



(I)

wherein X represents OH, (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂;

R₁ is a residue derived from one of the amino acids Phe, Tyr, Trp, Pro, which each may be optionally substituted with one or more (C₁₋₅) alkoxy groups, (C₁₋₅) alkyl groups or halogen atoms, as well as Ala, Val, Leu or Ile;

R₂ is a residue derived from one of the amino acids Gly, Ala, Ile, Val, Ser, Thr, Leu and Pro;

Y₁ and Y₂ independently from each other represent H or (C₁₋₅) alkyl;

R₃ and R₄ independently from each other represent H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy; and

R₅ represents H, OH, (C₁₋₅) alkyl or (C₁₋₅) alkoxy;

or a pharmaceutically acceptable salt thereof;

~~for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.~~

2. (currently amended) The use method according to claim 1, wherein X represents (C₁₋₅) alkoxy, NH₂, NH-C₁₋₅-alkyl, or N(C₁₋₅ alkyl)₂.

3. (currently amended) The use method according to claim 1 or 2, wherein R₃ and R₄ independently from each other represent H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy, provided that R₃ and R₄ are not both OH or (C₁₋₅) alkoxy.

4. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₅ represents H, (C₁₋₅) alkyl or (C₁₋₅) alkoxy.

5. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₁ is a residue which is derived from one of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom, or which is derived from Ile.

6. (currently amended) The use method according to claim 5, wherein R₁ is a residue which is derived from Phe, which may optionally be substituted with a (C₁₋₅) alkoxy group, a (C₁₋₅) alkyl group or a halogen atom.

7. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein R₂ is a residue which is derived from the amino acid Gly or Ile.

8. (currently amended) The use method according to ~~any of the previous claims~~ claim 1, wherein in the compound of formula (I) is glycyl-L-phenylalanyl-L-prolineamide, N,N-diethyl-

isoleucyl-phenylalanyl-L-proline ethylamide, N,N-diethyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.